Skip to main content
Saturday 3 June 2023
twitter linkedin facebook rss
User account menu
  • Sign up
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
  • Webinars
  • Podcasts
  • Videos
  • White Papers
  • Events
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
twitter linkedin facebook rss
Sign in

clinical trial

2016

Views & Analysis
INC ideathon event

Exclusive coverage of the 2016 inaugural 'Inspiring Hope' Id...

Views & Analysis
ESMO2016

ESMO review: advances in immunotherapy, EMA dialogue and pa...

QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s European Society for Medical Oncology (ESMO) congress in Copenhagen.

ESMO2016
ESMO16

Cancer Market Commentary: Keytruda’s triumph not the last wo...

Immunotherapies have been centre stage at this year’s ESMO cancer congress in Copenhagen, and the exceptionally good results from Keytrud

Views & Analysis
Kantar ESMO Main

Eye on ESMO 2016

Views & Analysis

The 2016 'Inspiring Hope' Ideathon - Day Two Coverage and re...

Views & Analysis
INC ideathon event

The 2016 'Inspiring Hope' Ideathon - Day One Coverage

  • Load more results

Editor's Picks

  1. Novartis buys Pharming priority review voucher for a song
  2. Elon Musk’s Neuralink says FDA has cleared human trial
  3. SNIPR shoots down resistant E. coli in first human trial
  4. Elizabeth Holmes due to start prison sentence
  5. UK funds extended reality projects for mental health
News

ASCO: Novartis touts Kisqali adjuvant breast cancer data

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte

R&D
pharmaphorum podcast episode 84

Inside the new world of healthcare data

These days, real-world data collection is in vogue and not hard to come by in healthcare research.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Frontiers Health 2022
    • The Future of Generics
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

 
 
rss facebook linkedin twitter
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2023, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – a Healthware Group company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2023, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – a Healthware Group company